SanBio Co., Ltd. engages in the development, production and sale of regenerative cells medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 29 full-time employees. The company went IPO on 2015-04-08. The firm has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The firm aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. The company is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The firm has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
최신 재무제표(Form-10K)에 따르면, SanBio Company Limited의 총 자산은 $15,621이며, 순손실입니다.
SNBIF의 주요 재무 비율은 무엇인가요?
SanBio Company Limited의 유동비율은 7.74이고, 순이익률은 0, 주당 매출은 $0입니다.
SanBio Company Limited의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
SanBio Company Limited 주요 수익원은 Banking and Related Activities이며, 최신 수익 발표에서 수익은 27,909,000입니다. 지역별로는 United States이 SanBio Company Limited의 주요 시장이며, 수익은 27,909,000입니다.
SanBio Company Limited은 수익성이 있나요?
no, 최신 재무제표에 따르면 SanBio Company Limited의 순손실은 $0입니다.